Dexcom tweaks full-year outlook after reporting 13% growth in Q2

Dexcom has somewhat raised its 2026 gross outlook astatine the low-end aft reporting Q2 gross of astir $1.3bn, indicative of a 13% uptick year-over-year (YoY).

The continuous glucose monitoring (CGM) specializer present expects its 2026 gross to onshore successful the $5.18bn to $5.25bn range, corresponding to a maturation borderline betwixt 11%-13% and up from $5.16bn to $5.25bn previously.

Dexcom released its Q2 results aft marketplace adjacent connected 30 July. Listed connected the Nasdaq exchange, the company's shares roseate by implicit 8% to $81.04 astatine marketplace unfastened connected 31 July, up from $74.54 previously. Dexcom has a marketplace headdress of astir $29bn.

The institution has achieved immoderate notable outcomes since reporting its Q1 results successful April. In June, the US Food and Drug Administration (FDA) cleared Dexcom's Stelo glucose biosensor strategy for children, making it the archetypal over-the-counter (OTC) continuous glucose show (CGM) for paediatric prediabetic and diabetic patients to beryllium cleared by the agency.

Meanwhile, Dexcom presented information highlighting the payment of its G7 continuous glucose show (CGM) successful benignant 2 diabetes (TD2) patients not receiving insulin astatine the 2026 American Diabetes Association's (ADA) Scientific Sessions successful June.

The CONNECT randomised controlled proceedings of 265 evaluable patients assessed G7's interaction connected humor glucose absorption and humor glucose (A1C) levels. At baseline, mean A1C was 8.8%, with 31% of participants having an A1C ≥9%.

Patients assigned G7 experienced, connected average, an A1C simplification of 1.6% astatine 26 weeks, indicative of a 0.9% greater A1C simplification versus the self-monitoring power group. For those with a higher archetypal A1C, the simplification was adjacent greater.

Dexcom's Q2 results besides travel its capitalist day. During the event, held connected 14 May, the institution outlined its semipermanent fiscal outlook, revealing that it aims to execute integrated top-line maturation exceeding 10% each twelvemonth done 2030.

As outlined successful a Form 8-K filed with the US Securities and Exchange Commission (SEC), Dexcom's longer-term fiscal aims besides see achieving a non-GAAP gross nett borderline betwixt 67% and 69% successful 2030, and a non-GAAP operating nett borderline betwixt 29% and 30%.

Dexcom's president and CEO, Jake Leach, commented: "This quarter's show and the palmy outcomes from our CONNECT proceedings reenforce our assurance successful the way up and presumption america good to present connected our long-range plan."

"Dexcom tweaks full-year outlook aft reporting 13% maturation successful Q2" was primitively created and published by Medical Device Network, a GlobalData owned brand.